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Abstract 
 
Natriuretic peptides, especially B-type natriuretic peptide (BNP), have primarily 
been regarded as biomarkers in heart failure (HF). However, they are also 
possible therapeutic agents due to potentially beneficial physiological effects. 
The angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril/valsartan, 
simultaneously augments the natriuretic peptide system (NPS) by inhibiting the 
enzyme neprilysin (NEP) and inhibits the renin-angiotensin-aldosterone system 
(RAAS) by blocking the angiotensin II receptor. It has been shown to improve 
mortality and hospitalisation outcomes in patients with HF due to left ventricular 
systolic dysfunction. The key advantage of sacubitril/valsartan has been 
perceived to be its ability to augment BNP, while its other effects have largely 
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been overlooked. This article highlights the important effects of 
sacubitril/valsartan, beyond just the augmentation of BNP.  
 
First we discuss how NPS physiology differs between healthy individuals and 
those with HF by looking at mechanisms like the overwhelming effects of RAAS 
on the NPS, natriuretic peptide receptor desensitisation and absolute natriuretic 
deficiency. Secondly, this review explores other hormones that are augmented by 
sacubitril/valsartan such as, bradykinin, substance-P and adrenomedullin that 
may contribute to the efficacy of sacubitril/valsartan in HF. We also discuss 
concerns that sacubitril/valsartan may interfere with amyloid β homeostasis with 
potential implications on Alzheimer’s disease and macular degeneration. Finally, 
we explore the concept of ‘auto-inhibition’ which is a recently described 
observation that humans have innate NEP inhibitory capability when natriuretic 
peptide levels rise above a threshold. There is speculation that auto-inhibition 
may provide a surge of natriuretic and other vasoactive peptides to rapidly reverse 
decompensation. We contend that by pre-emptively inhibiting NEP, 
sacubitril/valsartan is inducing this surge earlier during decompensation, 
resulting in the better outcomes observed.  
 
 
  
 
 
 
 
 
 
Introduction  
 
Sacubitril/valsartan is the first in a new class of drug: the angiotensin receptor - 
neprilysin inhibitors (ARNI). Its mechanisms of action have not been well 
defined. Sacubitril/valsartan causes simultaneous augmentation of the natriuretic 
peptide system (NPS) and inhibition of the renin-angiotensin-aldosterone system 
(RAAS).1 RAAS inhibition by valsartan has been extensively tested in patients 
with heart failure (HF).2 Therefore, in this article we shall focus on the actions of 
sacubitril, which are less well understood.  
The Prospective Comparison of ARNI [Angiotensin Receptor–Neprilysin 
Inhibitor] with ACEI [Angiotensin-Converting– Enzyme Inhibitor] to Determine 
Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-
HF) trial,3 which was stopped early due to overwhelming benefit, reported an 
impressive 20% relative risk reduction (4.7% absolute risk reduction) in the 
primary outcome of HF hospitalisation or cardiovascular (CV) death with 
sacubitril/valsartan when compared to enalapril. The beneficial effect of 
sacubitril/valsartan has been perceived to be due to  its effect on the NPS, while 
its other effects have largely been overlooked. This has led some to think that 
increasing the already elevated natriuretic peptide hormones in heart failure even 
further will be of little benefit. Indeed, trials testing other methods of modulating 
the NPS in acute HF, such as by supplementing exogenous natriuretic peptides, 
direct NEP inhibition or dual inhibition of NEP and ACE, have been 
disappointing. (Table 1)   
The purpose of this review is to understand the effects of sacubitril/valsartan on 
the NPS and other vasoactive systems, and to explore alternate mechanisms that 
account for not only the beneficial effects, but also possible off-target effects seen 
with sacubitril/valsartan.  
 
The Natriuretic Peptide System  
 
There are a number of natriuretic peptides that play an important role in CV 
homeostasis, namely atrial natriuretic peptide (ANP), B-type natriuretic peptide 
(BNP), C-type natriuretic peptide (CNP), dendroaspis-type natriuretic peptide 
(DNP), and urodilatin.4 ANP and BNP are predominantly produced by the atria 
and ventricles respectively in response to volume/pressure overload.4 (Figure 1) 
They both increase glomerular filtration rate, and enhance sodium and water 
excretion in the kidneys.5 They also promote vasodilatation, antagonise 
vasoconstriction and increase capillary permeability, causing fluid loss into the 
extravascular compartment.6 Additionally, natriuretic peptides inhibit the 
secretion of renin and aldosterone, and antagonise the sympathetic system.6  
 
All natriuretic peptides act on two guanylate cyclase-linked transmembrane 
receptors, natriuretic peptide receptor (NPR) A and B. NPR-A primarily binds to 
ANP and BNP, whereas NPR-B has a higher affinity for CNP.7 When activated 
the guanylate cyclase moiety within the receptor catalyses the production of 
second messenger cyclic guanosine monophosphate (cGMP) from guanosine 
triphosphate (GTP). This cGMP pool then mediates a variety of downstream 
signalling cascades in the target organs (vascular endothelium, cardiac myocytes 
and fibroblasts, zona glomerulosa of the adrenal cortex and renal epithelial cells).7  
(Figure 2)  
 
Unlike most other receptor classes, NPR-A and NPR-B are single-molecule trans-
membrane receptors that do not require internalisation when a ligand binds.6 
Consequently, they cannot be down-regulated.8 Nevertheless, long term exposure 
to high concentrations of natriuretic peptides results in receptor desensitisation 
secondary to dephosphorylation,8 meaning the receptor concentration and binding 
capacity remain unchanged but the receptors are unable to generate the same 
second messenger response as before. 
 
NPR-C, functions as a clearance receptor. It binds to all natriuretic peptides and 
internalises them for lysosomal hydrolysis.9 Unlike NPR-A and NPR-B, it has 
three distinct domains (extracellular, transmembrane and intracytoplasmic) and 
can therefore undergo down-regulation.  NPR-C is the most abundant class of 
NPR, comprising more than 95% of the total NPR population, and is thus the 
dominant mode of natriuretic peptide clearance.6  
 
An alternative metabolic pathway for natriuretic peptides is hydrolysis by a 
membrane bound metalloproteinase called neprilysin or neutral endopeptidase 
24.11 (NEP). It is distributed widely (brain, eyes, lungs, intestines, fibroblasts) 
but is predominantly found in the brush border of proximal tubular cells in the 
kidneys.10 NEP metabolism is a minor contributor to natriuretic peptide clearance 
under normal conditions but becomes the dominant clearance pathway in disease 
states such as HF, when clearance via the NPR-C pathway becomes saturated (or 
down-regulated following chronic exposure).11 
 
The Natriuretic Peptide Paradox of Heart Failure 
 
The mechanisms discussed above describe the function and action of the NPS in 
isolation. In a healthy individual, these mechanisms hold true, but in HF a very 
different picture emerges. In chronic HF, patients develop a state of resistance to 
natriuretic peptides,12 such that despite persistently elevated natriuretic peptide 
levels, patients remain congested. This then raises the question: why would 
increasing natriuretic peptides further by using a drug like sacubitril/valsartan be 
beneficial? To answer this fundamental question, we will need to first understand 
the pathophysiology behind this ‘natriuretic peptide paradox’.13 A number 
theories have been proposed, and the true mechanism behind this phenomenon 
may well be a combination of the following theories: 
 
a. Overwhelming effects of the RAAS on the actions of natriuretic peptides 
In healthy individuals, there is an inverse relationship between ANP and renin 
suggesting the NPS and RAAS are mutually antagonistic. However, this 
relationship is lost in patients with HF, who exhibit a positive correlation 
instead.14 This reflects the simultaneous activation of both the NPS (as a result of 
atrial distension and increased ventricular end diastolic pressure) and RAAS (due 
to reduced blood pressure and renal perfusion pressure).15 Even though most of 
the effects of the NPS are opposed to the RAAS, the RAAS is capable of 
overwhelming the NPS; angiotensin II (Ang II) attenuates the natriuretic effect 
of ANP in the kidneys of healthy individuals.16 Additionally, angiotensin and 
vasopressin desensitise vascular ANP receptors in the rat, perhaps via protein 
kinase C activation, thereby suppressing NPR-A second messenger cGMP 
production.17 
 
 
b. Receptor desensitisation: 
Tsutamoto et al. demonstrated that patients with chronic HF had higher ANP 
extraction (i.e. binding of ANP to its receptor) but lower cGMP (second 
messenger) production than those with acute HF. This suggests that although 
patients with chronic HF have more receptors, they were unable to produce the 
same amount of cGMP. More importantly, they also demonstrated that it was the 
duration of HF and not the severity of HF that determined receptor 
desensitisation.12 The mechanism behind the desensitisation of chronically 
ligand-bound natriuretic peptide receptors has been attributed to the 
dephosphorylation of their kinase domains.  This prevents the receptors from 
undergoing the conformational change required to activate the guanylate-cyclase 
moiety responsible for the conversion of GTP to cGMP.18 (Figure 2)  
 
 
c. Natriuretic peptide deficiency:  
Some studies have suggested that the predominant portion of circulating BNP in 
patients with advanced HF is unprocessed proBNP (BNP1-108), and not the 
biologically active BNP (BNP32), suggesting that patients actually have a state of 
natriuretic peptide deficiency;19 in other words, the myocardium continues to 
produce the natriuretic peptide prohormones in response to the volume and 
pressure stressors of HF, but these prohormones are not being processed into their 
biologically active forms.  
 
Corin is the cardiac transmembrane serine protease which is the putative major 
convertase enzyme for both proANP and proBNP.20 Some studies have suggested 
that patients with advanced heart failure are unable to mount a natriuretic 
response because of corin dysregulation, resulting in unprocessed proBNP 
(BNP1-108) being the predominant portion of circulating BNP, instead of the 
biologically active BNP (BNP32). (Figure 1) In a small study using novel 
immunoassays, patients presenting with acute HF had plasma corin levels less 
than one eighth of those in healthy individuals.21 Plasma corin levels were also 
lower among patients with chronic HF compared to healthy controls, and were 
inversely correlated with the severity of heart failure.  
Additionally, commercial antibody-based enzyme-linked immunosorbent assay 
(ELISA) detection methods are unable to distinguish between unprocessed BNP1-
108, active BNP32 or fragments of the two (e.g. BNP1-30, BNP3-32, BNP4-32 and 
BNP5-32). Among HF patients, mass spectrometry analysis suggests that the true 
levels of BNP32 (active BNP) were significantly lower than those measured by 
ELISA.20 The ELISA-based BNP assays cross-react with BNP1-108 and its 
breakdown fragments leading to spuriously high measured BNP levels in patients 
who are actually (BNP32) deficient.
22 
 
Pharmacology of sacubitril/valsartan 
 
Sacubitril/valsartan is a novel compound that combines sacubitril and valsartan 
in a salt delivering a 1:1 molar ratio of its constituents after oral administration.23 
Valsartan is an angiotensin receptor blocker with proven efficacy in 
cardiovascular disease.24 Sacubitril is a prodrug and is metabolised to sacubitrilat 
(LBQ 657), which then inhibits NEP.23 With the mean elimination half-lives of 
sacubitril, sacubitrilat and valsartan being 1.4 hours, 11.5 hours and 9.9 hours 
respectively,23 sacubitril/valsartan is suitable for once daily administration, 
although it is used as a twice daily preparation in heart failure to ensure a 
sustained and uninterrupted effect on both NPS and RAAS.25 
The direct consequence of NEP inhibition is an increase in circulating natriuretic 
and other vasoactive peptides. NEP does not break down natriuretic precursor 
molecules such as proBNP or its N-terminal (NT) fragment, and their plasma 
levels are therefore not directly affected by NEP inhibition.26 ProBNP and NT-
proBNP thus remain useful biomarkers in patients treated with 
sacubitril/valsartan. (Figure 3) In fact, NT-pro-BNP is indirectly reduced by 
sacubitril/valsartan in HF  as a consequence of reduced ventricular wall stress.27  
 
Sacubitril/valsartan and its effects on other peptide 
hormones 
 
It is unlikely that the benefits reported in the PARADIGM-HF trial are 
attributable solely to inhibition of RAAS and potentiation of NPS by 
sacubitril/valsartan. NEP is a ‘promiscuous enzyme’ with a long list of potential 
substrates including enkephalins, oxytocin, gastrin, Ang I and II, endothelin-1, 
adrenomedullin, substance P, and bradykinin25 (each with its own kinetics). In 
vitro studies show that NEP has a far greater affinity for some of these peptides 
than for BNP (Table 2), suggesting that other peptides may be involved (at least 
in part) in producing the beneficial effects reported in PARADIGM-HF. (Figure 
4) The effects of sacubitril on other peptides have not been fully explored in 
humans, however there is animal data that signal potential benefits. . 
 
Substance P and bradykinin have frequently been blamed for such adverse effects 
of ACE inhibitors as dry cough and angioedema. In clinical trials testing 
omapatrilat (a drug that simultaneously inhibits ACE and NEP), there was 
marked increase in angio-oedema.1 This was attributed to excessive potentiation 
of bradykinin and substance P levels due to the inhibition of ACE, NEP and 
aminopeptidase P.1 Nevertheless, substance P and bradykinin have also shown 
potential CV benefit. 28 29   
 
a. Substance P 
Substance P is a vasoactive neuropeptide that is also found in the human heart 
including the adventitia of the coronary vessels30 and between the 
cardiomyocytes.31 It is secreted by endothelial cells in response to sheer stress to 
produce vasodilatation in the coronary vasculature by binding to neurokinin 
(NK)-1 receptors, which releases nitric oxide.32  
 
Animal ischaemia reperfusion studies show substance P having a protective effect 
by increasing coronary perfusion and attenuating hypoxic cellular damage.33 
However chronic exposure to substance P induces inflammation, apoptosis and 
matrix metalloproteinase activation which result in adverse remodelling.33  
 
b. Bradykinin: 
Bradykinin is another potent vasodilatory peptide that acts via B2 kinin receptors 
in the vascular endothelium to stimulate the synthesis of nitric oxide, prostacyclin 
and endothelium-derived hyperpolarising factor resulting in vasodilatation.34 It 
preferentially increases blood flow to the subendocardium,34 thus improving 
transmural myocardial perfusion. Increased bradykinin levels due to ACE-
inhibition result in reduced renal vascular resistance due to selective efferent 
arteriolar dilatation.35 The salutary effects of bradykinin potentiation as a result 
of ACE inhibition is seen in in patients with36 and without HF.37   
 
c. Adrenomedullin  
Adrenomedullin is synthesized in a variety of tissues including the adrenal 
glands, endothelium, vascular smooth muscles, renal parenchyma and cardiac 
myocytes. It has multiple potentially beneficial effects such as vasodilatation, 
anti-proliferation, increased renal blood flow, natriuresis and diuresis.38 Clinical 
studies show that adenomedullin reduces pulmonary capillary wedge pressure, 
increases cardiac index and increases urinary volume and sodium excretion in 
patients with HF.39  
 
Effects of sacubitril/valsartan on amyloid β 
 
The pathophysiology of Alzheimer’s disease (AD) is complex. The leading 
hypothesis behind AD suggests late onset AD (the commonest type of AD) to be 
the sequelae of reduced amyloid β clearance.40 There are two mechanisms for 
amyloid β clearance, namely enzymatic or non-enzymatic (transport proteins) 
clearance. NEP is involved in the enzymatic clearance of amyloid β. Clinical 
studies show declining expression of NEP in the hippocampus and midtemporal 
gyrus of patients with AD in parallel with increasing deposition of amyloid 
plaques,41 while areas that are resistant to amyloid plaque deposition, such as the 
caudate nucleus, show increased NEP expression.42 
 
There was no increase in the risk of dementia or cognitive decline over the median 
follow-up time of 27 months in the patients treated with sacubitril/valsartan in 
PARADIGM-HF.43 In young cynomolgus monkeys, sacubitril/valsartan resulted 
in increased amyloid β in the cerebrospinal fluid (CSF) but there were no amyloid 
plaques in the brain parenchyma.23 A study on healthy volunteers over 2 weeks 
showed that sufficient concentration of sacubitrilat was achieved in the CSF to 
inhibit NEP in the brain.  There was an increase in the amyloid β1-38 isoform 
which is hydrophilic and does not aggregate to form amyloid plaques. Levels of 
amyloid β1-40 and β1-42 concentrations in the CSF (which do form amyloid 
plaques) were unchanged from baseline.44 These and other pre-clinical studies45 
seem to suggest that although NEP inhibition in the brain results in a net increase 
in total amyloid concentration, the increase is primarily driven by the soluble, 
non-plaque forming, amyloid β1-38 isoform. Further evaluation is required as 
these observations were made over the short term in young and healthy subjects. 
 
As a result of the possible risk of AD, there is now a trial investigating the effects 
of sacubitril/valsartan compared to valsartan on cognitive function in patients 
with HF. As part of the trial, the US Food and Drug Administration (FDA) has 
suggested a comprehensive battery of neurocognitive tests as well as positron 
emission tomography studies. (Clinical trials identifier: NCT02884206) Results 
are expected in 2022.46 
 
In the eye, amyloid β deposits have been linked to age-related macular 
degeneration (AMD). NEP deficient mice develop retinal pigment epithelial cell 
degeneration and sub-retinal deposits that result in AMD.47 This is reversed when 
the catalytic domain of NEP is administered into the vitreous humour of a mouse 
model of retinal degeneration.48 There are no published data on the effects of 
sacubitril/valsartan on the eye in humans.  
 
 
Auto-inhibition of neprilysin  
 
Vodovar and colleagues studied 684 patients, 468 of whom had decompensated 
HF.49 They found that raised BNP (above 916 pg/ml) was associated with reduced 
circulating NEP activity. They then incubated the plasma of age-matched healthy 
controls with either high or low concentrations of recombinant BNP. NEP activity 
was much lower in the plasma incubated with high levels of BNP, even though 
the NEP concentration was the same in both groups.  
 
These data suggest that BNP acts as a ‘molecular switch’, high concentrations of 
which can inhibit the activity of NEP thereby inducing a further accumulation of 
natriuretic peptides and other vasoactive peptides that are substrates of NEP 
(including substance P, bradykinin and adrenomedullin).49 
 
This phenomenon of NEP ‘auto-inhibition’ by BNP raises a theoretical possibility 
that sacubitril/valsartan will have little benefit beyond that of angiotensin receptor 
blockade (conferred by the valsartan component) in patients with advanced HF 
and very elevated BNP (who consequently will have NEP auto-inhibition), 
rendering the sacubitril component redundant. Although recent post-hoc analysis 
of the PARADIGM-HF dataset showed the benefit of sacubitril/valsartan was 
seen regardless of baseline BNP levels,50 the only way this question can reliably 
be answered is by a clinical trial. Indeed, the LIFE-HF trial (NCT02816736) will 
be attempting to answer this question.  
Pre-empting HF decompensation   
 
In a patient with compensated HF, NPR-C is the dominant clearance pathway for 
the NPS. However, when the patient decompensates and starts to produce large 
quantities of natriuretic peptides, the NPR-C receptors become saturated and the 
NEP pathway becomes the primary pathway for clearance.6 In a rat model, 
inhibition of NEP alone does not affect the plasma half-life of ANP. However, 
blocking NPR-C (thereby simulating the NPR-C saturation seen in HF) doubles 
the half-life of BNP, and blockade of both NEP and NPR-C prolongs it further.11 
Sacubitril thus probably has little effect in patients with compensated HF because 
in that state NEP is only a minor metabolic pathway.  
 
A New Paradigm in Heart Failure   
 
It is important to remember that compensated HF and (acute) decompensated HF 
are two ends of the same disease spectrum. The discussion above regarding NEP 
auto-inhibition and NPR-C clearance seem to suggest that sacubitril/valsartan 
would probably be most effective in the area between the two ends of the HF 
spectrum. 
When a stable patient already on sacubitril/valsartan starts to decompensate 
(thereby saturating their NPR-C receptors), the pre-emptively inhibited NEP 
starts to have a multiplicative effect on the rising levels of its substrates, as 
illustrated in figure 5. This results in a surge in the activity of not only the NPS 
but also other vasoactive hormones such as substance P, bradykinin and 
adrenomedullin. This early and pronounced burst of activity has 
haemodynamically beneficial effects (such as coronary and systemic 
vasodilatation, diuresis, reduced sympathetic activity), thereby arresting the 
decompensation. As a result of fewer episodes of decompensation, we can expect 
to delay the progression of heart failure. (Figure 5) 
 
It may well be that this ability to dynamically modulate the natriuretic and 
vasoactive peptide systems is what sets sacubitril/valsartan apart from the other 
HF therapies that have more static pharmacodynamic profiles which are unable 
to respond as the patient moves along the HF spectrum.  
 
Conclusions 
 
With recent approvals from the FDA, the European Medicines Agency and the 
National Institute for Health and Care Excellence, sacubitril/valsartan is poised 
to change the way we treat patients with HF. It is unlikely that all the benefits of 
sacubitril/valsartan can be explained simply by its effects on the NPS or BNP 
alone. The complete mechanism of benefit of sacubitril/valsartan is not yet fully 
elucidated and only with more rigorous research will it become clear. It is 
imperative that we understand how this drug affects the various hormonal 
pathways, not only to ensure its appropriate use and to recognise its limitations, 
but also to help guide the development of newer therapies with other targets. 
Table 1. Comparison table of trials testing treatment that modulate the 
natriuretic peptide system.   
Footnote: VMAC= Young et al. Vasodilation in the Management of Acute 
Congestive Heart Failure. Circulation 2000;102:2794. ASCEND-HF= O'Connor 
et al. Effect of nesiritide in patients with acute decompensated heart failure. The 
New England journal of medicine 2011;365(1):32-43. META-ANALYSIS= 
Sackner-Bernstein et al. Risk of worsening renal function with nesiritide in 
patients with acutely decompensated heart failure. Circulation. 
2005;111(12):1487-1491. U.S. Ecadotril Pilot Safety Study= O’Connor et al. A 
randomized trial of ecadotril versus placebo in patients with mild to moderate 
heart failure: the US ecadotril pilot safety study. Am. Heart J. 138,1140–1148. 
International, Multicentre Ecadotril Dose-ranging Study=Cleland et al. Lack 
of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The 
International Ecadotril Multicentre Dose-Ranging Study Investigators. Lancet 
351, 1657–1658. Northridge et al.= Northridge et al. Placebo-controlled 
comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and 
captopril in patients with chronic heart failure. European Journal of Heart 
Failure 1999;1(1):67-72. Westheim et al.= Westheim et al. Hemodynamic and 
neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart 
failure. Journal of the American College of Cardiology. 15 Nov 1999;34(6):1794-
1801. Kentsch et al.= Kentsch et al. Neutral endopeptidase 24.11 inhibition may 
not exhibit beneficial haemodynamic effects in patients with congestive heart 
failure. European journal of clinical pharmacology 1996;51(3-4):269-272. 
IMPRESS= Rouleau et al. Comparison of vasopeptidase inhibitor, omapatrilat, 
and lisinopril on exercise tolerance and morbidity in patients with heart failure: 
IMPRESS randomised trial. Lancet. 2000;356(9230):615-620. OVERTURE= 
Packer et al. Comparison of omapatrilat and enalapril in patients with chronic 
heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in 
Reducing Events (OVERTURE). Circulation. 2002;106(8):920-926. 
OCTAVE= Kostis et al. Omapatrilat and enalapril in patients with hypertension: 
the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. 
American journal of hypertension. 2004;17(2):103-111. PARADIGM-HF= 
McMurray et al. Angiotensin-neprilysin inhibition versus enalapril in heart 
failure. The New England journal of medicine. 2014;371(11):993-1004. 
PARAMOUNT= Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor 
neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a 
phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387-
1395. PARAGON= Clinical trials identifier: NCT01920711.  
 
Table 2. Peptide substrates of neprilysin.51  
Footnote: Km=Michaelis constant - the concentration of a substrate which allows 
the enzyme to achieve half of maximum reaction velocity, it is the inverse 
measure of affinity of an enzyme to its substrate (ie. lower the Km, the higher the 
affinity of an enzyme to the substrate); Kcat=catalytic production rate under 
optimum conditions; Kcat/Km= comparison ratio that allows for evaluation of 
the efficiency of an enzyme on different substrates 
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FIGURE LEGENDS  
Figure 1. The stimulus for and sites of synthesis of ANP, BNP and CNP.  
ANP=Atrial natriuretic peptide; BNP=B-type peptide; CNP=C-type peptide; 
NT=N-terminal; LA=left atrium; RA=right atrium; LV=left ventricle; RV=right 
ventricle; EDP=end diastolic pressure; 
 
Figure 2. The mechanism of action and the pathways of metabolism of ANP, 
BNP and CNP.  
ANP=Atrial natriuretic peptide; BNP=B-type peptide; CNP=C-type peptide; 
NPR=natriuretic peptide receptor; NEP=neprilysin, GTP=guanosine 
triphosphate; cGMP=cyclic guanosine monophosphate, CV=cardiovascular  
 
Figure 3. Schematic representation of mechanism of sacubitril/valsartan on the 
natriuretic peptide and renin-angiotensin-aldosterone systems.  
BNP= B-type natriuretic peptide; Na= Sodium; ACE=angiotensin converting 
enzyme 
 
Figure 4. Overview of pathophysiological effects of HF and the multi-modal 
mechanisms of sacubitril/valsartan in reversing those effects. Detrimental effects 
coloured grey, beneficial effects of sacubitril/valsartan coloured blue (NPS) and 
red (RAAS). 
NPS=natriuretic peptide system; NP= natriuretic peptide; ANP=atrial natriuretic 
peptide; BNP=B-type natriuretic peptide; CV=cardiovascular; BP= blood 
pressure; RAAS=renin-angiotensin-aldosterone system; AT=angiotensin; 
?=unknown or theoretical effect 
 
Figure 5. Hypothetical excursions of natriuretic and other vasoactive peptides 
(eg bradykinin, substance P and adrenomedullin) during episodes of acute 
decompensated heart failure (blue line) and baseline (compensated) BNP levels 
(red line).  
Figure 5a. Patients not on sacubitril/valsartan gradually increase natriuretic and 
vasoactive peptide levels in response to decompensation. This delays the onset of 
the beneficial effects of these peptides that can only manifest after overcoming 
natriuretic peptide receptor desensitisation and the counter-regulatory effects of 
RAAS.  
  
Figure 5b. Patients on sacubitril/valsartan will already have neprilysin inhibition 
prior to decompensation. When an episode of decompensation occurs, natriuretic 
and vasoactive peptide levels rise rapidly and begin to manifest their effects 
earlier. This may abort the decompensation altogether or shorten its duration 
(possibly accounting for the fewer hospitalisations seen in PARADIGM-HF).  
These fewer and shorter episodes of decompensated heart failure result in less 
sequelae, manifested by a more gradual rise in BNP levels (perhaps explaining 
the mortality benefit seen in PARADIGM-HF).  
 
 
 
 
 
 
 
 
 
DRUG TRIAL NAME 
(patients recruited)  
CONDITION  
 (study arms) 
FINDINGS  
(in treatment arm)  
NESIRITIDE VMAC 
(n=489)  
ADHF 
 
(Nesiritide vs IV GTN vs 
Placebo) 
 Improved PCWP and all PA 
pressures within 15 minutes 
 Improved dysponea at 3 hours 
 
 
ASCEND-HF 
(n=7141)  
ADHF 
 
(Nesiritide vs Placebo)  
 Signal of improved dyspnoea (not 
significant)  
 No 30 day mortality / re-
hospitalisation benefit  
 No effect on urine output  
 No worsening renal function 
 More hypotension 
  
META ANALYSIS: Risk of 
worsening renal function 
(n=1269) 
ADHF  
 
(Nesiritide vs Inotropic / 
Non-inotropic control) 
 Worsening renal function 
compared to inotrope / non-
inotrope controls  
 Worsening renal function at any 
dose of nesiritide  
 No difference in need for dialysis 
 
ECADOTRIL U.S. Ecadotril Pilot 
Safety Study  
(n=50)  
 
CHF (NYHA II-III)  
 
(Ecadotril 50-400 mg vs 
placebo)  
 Dose-ranging study for 10 weeks 
 No difference in patient assessed 
symptoms  
 No difference in NYHA class 
 No safety signal raised  
International, 
Multicentre Ecadotril 
Dose-ranging Study  
(n=279)  
CHF (NYHA II-III)  
 
(Ecadotril 50, 100, 200 and 
400mg vs placebo)  
 International dose-ranging study 
for 13 weeks.  
 Plasma and urinary cGMP 
increased 
 No difference in patient assessed 
symptoms  
 No difference in NYHA class 
 Increased occurrence of aplastic 
anaemia – clinical development of 
drug halted.   
CANDOXATRIL Northridge et al.  
(n= 60)  
CHF (NYHA I-III)  
 
(Candoxatril vs Captopril vs 
placebo)  
 
 Signal of better improvement in 
exercise tolerance in candoxatril 
arm at 12 weeks (not significant)  
 Trend for improved NYHA class 
and subjective quality of life in 
both active drug groups (not 
significant)  
 
Westheim et al. 
(n= 47 )  
 
CHF (NYHA I-II)  
 
(Candoxatril vs Furosemide 
vs placebo)  
 Candoxatril and Furosemide, 
compared to placebo, significantly 
reduce PCWP at day 0 but 
Candoxatril arm no longer 
significant at day 42  
 Improved cardiac index in both 
groups at day 0 (Candox > Furo)  
Table 1. 
 No change in renin, angiotensin II, 
aldosterone, noradrenaline activity 
in Candoxatril arm at day 0 or 42 
 
Kentsch et al. 
(n=24)  
CHF  
 
(Candoxatril vs placebo)  
 Increased plasma cGMP (second 
messenger of ANP)  
 Dose dependent increase in PVR & 
reduction in cardiac index  
 
 
 
 
OMAPATRILAT IMPRESS 
(n=573) 
CHF (NYHA II-IV) 
 
(Omapatrilat vs Lisinopril) 
 Improved NYHA class among NYHA 
class III & IV patients  
 Minimal improvement in exercise 
treadmill test (not significant)  
 Signal of reduced death or HF 
admission (not significant)  
 
OVERTURE 
(n=5770)  
CHF (NYHA II-IV)  
 
(Omapatrilat vs Enalapril)  
 Non-inferior to enalapril in 
preventing death or HF 
hospitalization requiring IV 
medication  
 Less death or all-cause HF 
hospitalization (post hoc analysis)  
 60% relative risk increase in 
angioedema  
 
OCTAVE 
(n= 25 302)  
Untreated / 
uncontrolled HPT 
 
(Omapatrilat vs Enalapril)  
 Reduced BP by 3.6/2.0 mmHg 
more than comparator  
 Less use of adjunctive anti-
hypertensives  
 More likely to reach BP targets 
regardless of demographics / 
comorbids  
 More frequent angioedema (2.17% 
vs 0.68%) - including 2 patients 
with airway compromise  
 
SACUBITRIL / 
VALSARTAN 
PARADIGM-HF 
(n=8442)  
CHF (NYHA II-IV & 
HFrEF: EF ≤ 40%)  
 
(Sacubitril/Valsartan vs 
Enalapril)  
 20% RRR in CV death or HF 
hospitalization  
 NNT to prevent 1 CV death = 32 
 Reduced systolic BP by 3.2 mmHg 
 Improved subjective quality of life   
 No significant difference in 
angioedema rates 
 
PARAMOUNT  
(n=301)  
CHF (NYHA II-III &  
HFpEF: EF ≥ 45%)  
 
(Sacubitril/Valsartan vs 
Valsartan)  
 Greater BP reduction - 9.3/4.9 
mmHg 
 Lower NT-proBNP by 12 weeks  
 LA dimension and volume lower at 
36 weeks  
 No difference ventricular volumes 
/ LVEF / diastolic function  
 Improved NYHA class at 36 weeks 
  
 
 
 
Table 2.  
 
Peptide Km 
(μM) 
Kcat 
(min-1) 
Kcat/Km 
(min-1 μM-1) 
β-amyloid protein 42 2.8 - - 
Pro-adrenomedullin  6.1 - - 
ANP28 28.3 145 5.1 
Substance P 31.9 5062 158.7 
Bradykinin 92.2 6364 69.0 
BNP32 102 54.3 0.53 
Angiotensin II 280 - - 
 
 
 Angioedema only in 1 patient in 
LCZ arm, nil in valsartan arm   
 
PARAGON-HF 
(currently recruiting)  
CHF (NYHA II-IV &  
HFpEF: EF ≥ 45%)  
 
(Sacubitril/Valsartan vs 
Valsartan)  
 Primary outcome: Composite CV 
death or HF hospitalisation 
 Secondary outcomes:  
o Cumulative CV death / total HF 
admissions / nonfatal MI or 
stroke 
o Change in NYHA class at 8 
months 
o Time to AF  
o Time to all cause death   
